Abstract
Surgical Aortic Valve Replacement (SAVR) is a relevant therapy for patients who need valve replacement according to Latin American guidelines, especially for those patients with a long-life expectancy. However, bioprothesis are not exempt from structural valve deterioration and reintervention at mid and long-term, which have been demonstrated in recent articles. Moreover, in a scenario with relevant budget restrictions, resource optimization has become more necessary than ever. Hence, we aimed to estimate the costs associated to the perioperative period and reinterventions in the long-term of 2 of the most frequently used pericardial valve prosthesis in Latin America, the Trifecta® (Trif) and the Magna Ease® (ME) aortic valves from payers perspective in Brazil (Private) and Mexico (Public).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
